Life sciences company Revvity (NYSE:RVTY) reported in Q4 CY2025, with sales up 5.8% year on year to $772.1 million. The company’s full-year revenue guidance of $2.98 billion at the midpoint came in ...
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Revvity management provided guidance for FY 2026, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results